Formosa Pharmaceuticals, Inc.

Investor's Meeting

See the power in the small.

January 23, 2026

FORMOSA
PHARMACEUTICALS, INC.
台新藥股份有限公司

DISCLAIMER

- The forward-looking information mentioned in this presentation and related information released simultaneously, including operational outlook and financial content, is based on the Company's assessment of current internal and external economic conditions.
- Actual future operational results, financial conditions, and business performance may differ from these forward-looking statements. These differences may arise from various factors, including but not limited to market demand, price fluctuations, competitive landscape, changes in laws, regulations, and the financial/economic environment, as well as other risks beyond the Company’s control.
- The information provided in this presentation reflects the Company’s views on the future as of the current date and constitutes no express or implied warranty regarding its accuracy, completeness, or reliability. The Company assumes no obligation to update or revise these views should they change or be adjusted in the future.

AGENDA

1. **Introduction to Formosa Pharma**
   Milestones | Board of Directors | Pipeline | Management
2. **Antibody-Drug Conjugates (ADCs)**
   HER2+ ADC Biosimilar | TSY-310 Bispecific ADC
3. **APNT Nanoparticle Formulation Technology**
   Nanolization Mechanism | Dosage Forms | Co-development
4. **BYQLOVI (APP13007) Nanosuspension**
   Features | License & Reg. | Market | Commercialization

ADC APNT
See the power in the small.

FORMOSA PHARMACEUTICALS, INC. 台新藥股份有限公司

Introduction to Formosa Pharma

Milestones | Board of Directors | Pipeline | Management

2023-2024 Launch & Listed

2017-2022 *Technical Foundation*

(2017) Acquired Activus Pharma (Japan).

(2021) Registered on the Emerging Stock Board, Ticker: 6838.

(2023) Obtained the "Technology Enterprise" approval letter from the IDA, MOEA.

(2024) Completed IPO listing.

(2017) Acquired the APNT nanoparticle formulation platform and R&D projects including APP13007.

(2019-20) Successfully completed US Phase 2 clinical trials for APP13007.

(2021-23) Successfully completed US Phase 3 clinical trials for APP13007.

Completed out-licensing of APP13007 for Mainland China, USA, Brazil, the Middle East, Canada, Switzerland, etc.

(2018) Acquired the technology for R&D project TSY-110.

(2022) Executed a co- development agreement for TSY-110 (EG12043) with EirGenix.

Introduction to Formosa Pharma

ADC APNT

See the power in the small.

2025-2026*

Expanding New Horizons

(2025) Complete out-licensing of APP13007 in multiple countries including India, South Africa, SEA, Mexico, Pan-Europe, and LatAm.

(2025) Submit registration dossiers for Canada, Taiwan, KSA, Israel, Switzerland, and South Africa.

(2026) Complete out-licensing of APP13007 for South Korean market.

(Ongoing) Recognized by various domestic and international partners, several APNT formulation studies are proceeding in parallel, including ophthalmic formulations, inhalation formulations, subcutaneous, and intra-articular injections, etc.

(2025) Acquire development rights for the bispecific antibody-drug conjugate ALM-401 (TSY-310).

(2025) Establish agreement with EirGenix for the development of TSY-120/EG12170 Enhertu biosimilar.

(Ongoing) TSY-110/EG12043 biosimilar is in preparation to begin clinical trials in 2026.

Dr. Chen-Yu Cheng, Ph.D.
Board Chairman

Dr. Jo Shen Ph.D.
Board Director

Dr. Weng-Foung Huang, Ph.D.
Board Director

Prof. Sophia Su, Ph.D.
Indep. Board Director

Dr. Leah Lo, Ph.D.
Indep. Board Director

Prof. Jaw-Jou Kang, Ph.D.
Indep. Board Director

Introduction to Formosa Pharma

Technology	Product Code	Indications	Progress					合作夥伴
			Pre-clinical	Phase I/II	Phase III	NDA/BLA	Commercialization	
APNT	APP13007	Pain & Inflammation following ocular surgery					US	HARROW Your patients. Our purpose.
						Non-US territories		Cipla, Grand Pharma, etc.
	APP13002	DED, Eye infections						
	APNT co-developments	Eye / Respiratory / Orthopedic / Skin diseases						Several biotech and research institutes
ADC	TSY-110 (EG12043)	HER2+ Breast Cancer						EirGenix
	TSY-120 (EG12170)	HER2+ driven cancers						EirGenix
	TSY-310	Solid Tumors						ALMAC

Introduction to Formosa Pharma

Milestones | Board of Directors | Pipeline | **Management**

Dr. Erick Co, Ph.D.
President & CEO

- ►Director of New Drug Development, ScinoPharm
- ►Nitto Denko Corp. Chief Sci. & Project Manager.
- ►Takeda Pharmaceuticals Senior Scientist
- ►Ph.D. in Organic Chemistry, UCLA

ScinoPharm Takeda Nitto

Mr. Wayne Wei, MPH
Chief Business & Strategy Officer

- ►VP of Intl. Sales Dept., Greenyn Biotech
- ►Intl. BD Manager, Standard Chem. & Pharm.
- ►VP of Intl. Business, Golden Biotechnology
- ►Master in Health Policy and Management, NTU

綠茵生技 Greenyn 國鼎生技 GoldenBiotech

Dr. Artemis Wu, Ph.D.
Director, Program Management

- ►Assistant Director, Allgenesis Biotherapeutics
- ►Project Lead, Twi Biotechnology
- ►Ph.D. in Mol. Biol. & Protein Biochem., NTU

Allgenesis twiB

Dr. Kuo-Ming Yu, Ph.D.
Director, CMC & Production

- ►R&D Manager, Tanvex BioPharma
- ►Avalon Biomedical Scientific Director
- ►Athenex, Inc. Director of Biologics
- ►Ph.D. in Biochemistry, The Hong Kong PolyU

tanvex AVALON BIOMEDICAL MANAGEMENT Athenex

Dr. YuChi Chen, Ph.D.
Director, Nanotechnology

- ►Prof., Department of Cosmetics, Vanung Univ.
- ►Postdoctoral Researcher, NHRI
- ►Ph.D. in Nutr. & Environ. Sci., Univ. of Shizuoka

Dr. I-Ting Ho, Ph.D.
Director, RA & QA

- ►Deputy Director of RA, Sunny Pharmtech
- ►Postdoc, Chem. Dept., UTexas, Austin
- ►Ph.D. in Applied Chemistry, NCTU

Sunny Pharmtech

FORMOSA PHARMACEUTICALS, INC. 台新藥股份有限公司


2
Antibody-Drug Conjugates (ADCs)
HER2+ ADC Biosimilar | TSY-310 Bispecific ADC
Taking the Lead: Tapping into the Multi-Billion Dollar ADC Market
ADC APNT

EirGenix

FORMOSA PHARMACEUTICALS, INC. 台新藥股份有限公司

TSY-110 / EG12043
TSY-120 / EG12170
Joint Development and Commercialization

FORMOSA LABORATORIES, INC.

- Leveraging Formosa Laboratories' leading ADC prodection capabilities and grasping the regulatory trend of Phase III clinical trial waivers for biosimilars in Europe and the US, it is expected to significantly accelerate the development timeline of ADC biosimilars and save development costs.
- Formosa Pharmaceuticals and EirGenix join forces to accelerate the development of Kadcyla biosimilar (TSY-110 / EG12043) and Enhertu biosimilar (TSY-120 / EG12170) projects in CMC development, clinical trials, and out-licensing.





Antibody-Drug Conjugates (ADCs)

HER2+ ADC Biosimilar | TSY-310 Bispecific ADC



Successful Launch and Continued Market Expansion of HER2+ ADC Drugs:

- HER2+ is one of the most popular therapeutic targets for ADCs.
- Roche's Kadcyla (First-in-class) and AstraZeneca & Daiichi Sankyo's Enhertu (Best-in-class) are the most representative HER2+ ADCs, and are leaders in ADC commercialization.
- By 2031, these two HER2+ ADC drugs are expected to reach a market scale of USD 13.3 billion.

GlobalData | Kadcyla.com | Enhertu.com | Roche | AstraZeneca | Daiichi Sankyo

FORMOSA PHARMACEUTICALS, INC. 台新藥股份有限公司

Antibody-Drug Conjugates (ADCs)

HER2+ ADC Biosimilar | TSY-310 Bispecific ADC

Product Overview

Reference ADC Drug：Kadcyla® （賀癌寧）

- Indication: HER2+ Breast Cancer.
- Plays a significant role in the treatment of both early and late-stage breast cancer.

Market Opportunity

Market Size: Global sales revenue of ~US$ 2.2 Bn.

- Kadcyla® holds a solid position in post-op adjuvant therapy and 2L treatment for metastatic BC.

Competitive Advantage

TSY-110: Opportunity to become the 1st ADC biosimilar launched in US and European markets.

Operational & Regulatory Advantages

Cost Advantage:
Commercial-scale production of EirGenix's Trastuzumab DS; Formosa Lab's ADC manufacturing is competitive.
Global Regulatory Advantage:
EirGenix's Trastuzumab antibody production facilities have been inspected and approved by authorities in the US, Taiwan, Japan, and the EU.

Product Launch Plan

Targeting market launch in 2029.
Expected to complete regulatory consultation meetings with the US FDA and EMA within 1H 2026 for securing a Phase 3 waiver, followed by the initiation of Phase 1(PK/BE) clinical trial and decision of out-licensing.

GlobalData | Kadcyla.com | Roche

FORMOSA PHARMACEUTICALS, INC. 台新藥股份有限公司

Antibody-Drug Conjugates (ADCs)

HER2+ ADC Biosimilar | TSY-310 Bispecific ADC



trastuzumab deruxtecan

Product Overview

Reference ADC Drug: Enhertu® （優赫得）

- Indication: HER2+ Breast Cancer, etc.
- In 2025, achieved clinical outcomes demonstrating efficacy superior to SOCs of the 1L MBC and EBC.

Competitive Advantage

TSY-120: Opportunity to become the first ADC biosimilar launched in US and European markets.

- Leverage the successful development experience of TSY-110 to create a first-mover advantage.

Market Opportunity

Market Growth: Has obtained over 10 approved indications. Projected to reach US$ 13.3 Bn by 2032.

Approved Indications：

Gastroesophageal junction gland cancer, bladder cancer, uterine neck cancer, large intestine cancer, uterine endometrial cancer, epithelial ovarian cancer, gastric cancer, HER2+ BC, HER2 Low BC, Metastatic biliary tract cancer, NSCLC, solid tumors.

Ongoing Clinical Indications：

Ductal cancer, cystic carcinoma, esophageal cancer, HER2- BC, TNBC, cerebral meningeal cancer, transitional pancreatic cancer, osteosarcoma, breast cancer brain transfer, GBM, urothelial cell carcinoma.

Antibody-Drug Conjugates (ADCs)

HER2+ ADC Biosimilar | TSY-310 Bispecific ADC

- TSY-310 is a bispecific Antibody-Drug Conjugate (ADC) targeting EGFR and ROR1, acquired by Formosa Pharma from Almac Discovery in 2025.
- The target indication is for the treatment of solid tumors such as Non-Small Cell Lung Cancer (NSCLC).
- TSY-310 has demonstrated durable and stable tumor regression effects in solid tumor models.



Therapeutic Targets:

ROR1 (Receptor tyrosine kinase-like Orphan Receptor 1) is a receptor protein expressed during embryonic development. It shows abnormal expression in lung cancer, breast cancer, and hematological malignancies, making ROR1 a highly potential anti-cancer target.

EGFR promotes tumor growth and metastasis and is a critical therapeutic target for various cancers.

Utilizing antibodies or ADCs targeting ROR1 allows for the selective killing of tumor cells, reducing damage to normal cells, thereby improving treatment safety and efficacy.

Antibody-Drug Conjugates (ADCs)

HER2+ ADC Biosimilar | TSY-310 Bispecific ADC

TSY-310 Molecule Structure and Features:

BISPECIFIC FORMAT



- Increased antigen binding, selectivity, and internalization
- Potential for high efficacy in drug-resistant environments



SINGLE-CHAIN ARCHITECTURE



- Easier to manufacture
- Long half-life

BIOENGINEERED MINIMAL SIZE



- Size is half of traditional mAbs
- Increased tumor penetration

SMALLER BINDING INTERFACE



- Small binding sites.

Antibody-Drug Conjugates (ADCs)

HER2+ ADC Biosimilar | TSY-310 Bispecific ADC

TSY-310 Demonstrates High Efficacy in ROR1 and EGFR Double-Positive CDX Models.

PC9 (Lung Adenocarcinoma CDX; EGFRm)





- Significant tumor regression was observed in the lung adenocarcinoma (EGFR mutant) model.

Antibody-Drug Conjugates (ADCs)

HER2+ ADC Biosimilar | TSY-310 Bispecific ADC

TSY-310 Demonstrates High Efficacy in ROR1 and EGFR Double-Positive CDX Models.

NCI-H1703 (Squamous NSCLC; EGFR Wild-Type)





- Significant tumor regression was observed in the squamous non-small cell lung cancer (EGFR wild-type) model.

Antibody-Drug Conjugates (ADCs)

HER2+ ADC Biosimilar | TSY-310 Bispecific ADC

TSY-310 Demonstrates Superior Efficacy in PDX Models Compared to ROR1 ADC - VLS-101 (MERCK)





- Significant tumor regression was observed in 9 out of 10 NSCLC PDX (Patient-Derived Xenograft) models. TSY-310 demonstrated consistent and superior efficacy compared to the clinical-stage ROR1 ADC (VLS-101) in both EGFR wild-type (wt) and mutant NSCLC PDX models.

Antibody-Drug Conjugates (ADCs)

HER2+ ADC Biosimilar | TSY-310 Bispecific ADC

TSY-310 Development Value

- **Novelty：** Combines the precision and efficacy of bispecific antibodies, with the potential to overcome the limitations of single-target ADCs and tumor heterogeneity.
- **Non-clinical Pharmacology：**
  - Demonstrates a significant **Bystander effect**.
  - Exhibits significant activity across dual-target animal models with varying expression levels.
- **Toxicity：** Utilizes clinically validated MMAE and linkers; potential off-target toxicity is known and controllable.
- **Clinical Value：** Expected to address unmet needs in solid tumors where **current EGFR therapies have failed or ROR1 treatments are ineffective**.



Bystander effect

Reference: Shi et al., Cancer Biology & Medicine, February 2025, 22 (2) 83-92.

Antibody-Drug Conjugates (ADCs)

HER2+ ADC Biosimilar | TSY-310 Bispecific ADC

TSY-310 is expected to fill the unmet medical needs of various marketed drugs and new drugs under development.

Therapeutic Class	Features	Unmet Needs / Limitations	Representative Drugs
TKI Small Molecule Inhibitors	For 1st to 3rd line EGFR treatment	**Drug resistance issues**	Erlotinib, Osimertinib (Tagrisso®)
EGFR Monospecific Monoclonal Antibodies	Effective against EGFR wild-type	**Drug resistance issues**	Cetuximab, Panitumumab
Bispecific Monoclonal Antibodies	Effective against single-target mutations	**Drug resistance issues**	Amivantamab (Rybrevant®, EGFR × MET)
ROR1 mAbs & ADC Candidates	Clinical trials demonstrate efficacy in hematological malignancies	**Limited efficacy in solid tumors**	Cirmtuzumab (Zilovertamab), Zilovertamab vedotin (VLS-101), CS5001



Currently no approved bispecific ADCs, highlighting the novelty and potential

Antibody-Drug Conjugates (ADCs)

HER2+ ADC Biosimilar | TSY-310 Bispecific ADC

Recent ADC licensing deals exceed USD $1 billion

Asset	Licensor	Licensee	Stage at Signing	Molecule Type	Indication	Upfront (US$M)	Total Value (US$M)	Date
IBI363 IBI343	Innovent Biologics Inc	Takeda Pharmaceutical	Phase I/II Phase III	PD-1/IL-2a-bias CLDN18.2 ADC	Squamous NSCLC, Gastric cancer, Pancreatic cancer	***1,200***	***11,400***	Dec-2025
SYS6005	CSPC Megalith Biopharmaceutical	Radiance Biopharma, Inc.	IND	ROR1 ADC	Hematologic tumors, etc.	***15***	***1,165***	Feb-2025
XNW27011	Evopoint Bioscience Co Ltd	Astellas Pharma Inc	Phase II	CLDN18.2 ADC	Solid Tumors	***130+70***	***1,540***	May-2025
MRG007	Lepu Biopharma Co Ltd	Arrivent Biopharma Inc	Preclinical	ADC (Unknown)	Gastrointestinal Cancers	***47***	***1,207***	Jan-2025
DB-1418	Duality Biotherapeutics Inc	Avenzo Therapeutics Inc	Preclinical	EGFR*HER3 ADC	Solid Tumors	***50***	***1,200***	Jan-2025
IBI3009	Innovent Biologics Inc	F. Hoffmann-La Roche Ltd	Phase I	DLL3 ADC	Advanced Small Cell Lung Cancer	***80***	***1,080***	Jan-2025
MTX-13 (DAY-301)	MabCare Therapeutics	Day One Biopharmaceuticals	IND	PTK7 ADC	Solid Tumors	***55***	***1,207***	Jun-2024
BNT326	Suzhou Medilink Therapeutics Ltd	BioNTech SE	Phase II	HER3 ADC	TNBC / NSCLC	***25***	***1,825***	May-2024
YL211	Suzhou Medilink Therapeutics Ltd	Roche	Phase I	cMET ADC	Solid Tumors	***50***	***1,020***	Jan-2024
LCB84	LigaChem Biosciences Inc	Janssen Biotech Inc	Phase II	Trop2 ADC	Advanced Solid Tumors	***100***	***1,700***	Dec-2023

3

APNT Nanoparticle Formulation Technology

Nanolization Mechanism | Dosage Forms | Co-development

Creating Opportunities: Pioneering the Blue Ocean for Poorly Soluble Drugs

ADC APNT

APNT Nanoparticle Formulation Technology

Nanolization Mechanism | Dosage Forms | Co-development





- **Development Challenge:** Up to **70%-90%** of new drug projects face development challenges due **to low water solubility**.
- **The Key to Unlocking Potential: APNT® technology** uses substances such as salts and sugars as excipients to grind poorly soluble drugs into **uniform nanoparticles (typically smaller than 200 nm)** that are easy to absorb.
- **Scientific Basis:** According to the **Noyes-Whitney equation**, increasing total surface area is the key to enhancing **dissolution rate** and **bioavailability**.

FORMOSA PHARMACEUTICALS, INC. 台新藥股份有限公司

APNT Nanoparticle Formulation Technology

Nanolization Mechanism | Dosage Forms | Co-development

Features of APNT® Nanoparticle Formulation Technology：

Low Contamination Risk

Uses FDA GRAS (Generally Recognized As Safe) certified salts/sugars as grinding media. Avoids abrasion residues associated with metal or plastic beads.

Maintains Crystalline Form & Purity

Utilizes a gentle process that does not employ high temperatures or organic solvents. Preserves the original crystal structure of the Active Pharmaceutical Ingredient (API).



Sterile Filtration Capable

Achieves uniform particle size <200 nm, capable of passing through 0.2-micron sterilization filters. This is the key to sterile manufacturing for ophthalmic and injectable formulations.

Excellent Stability

Nano-suspensions can maintain uniform dispersion for long periods.
Solves the pain points of traditional suspensions, which require vigorous shaking and often result in uneven dosing.

Proven Druggability

APP13007 has been approved by the US FDA. Successfully resolved the development challenge of extremely low solubility for Clobetasol Propionate.

FORMOSA PHARMACEUTICALS, INC. 台新藥股份有限公司

APNT Nanoparticle Formulation Technology

Validation of APNT® Nanoparticle Formulation in Different Fields :

Ocular

8x
Aqueous humor concentration

6x
Corneal exposure

5x
Conjunctival concentration

Oral

Curcumin Case –
Pharmacokinetics studies shows that compared to commercial powder, after APNT processing:

8.5x
Increase in Cmax

5x
Increase in AUC

Respiratory

Antibiotic Case – Tested using a Mesh Nebulizer, the APNT formulation (D90 < 250 nm) demonstrated:

Higher delivered dose

Shorter treatment time

APNT Nanoparticle Formulation Technology

Nanolization Mechanism | Dosage Forms | Co-development

Selected APNT nanoparticle formulation development projects; co-development will commence following the completion of Proof of Concept (POC) for each project.



In collaboration with a **national-level ophthalmology research institute** in an advanced country. Potential application **in various ocular surface diseases** that currently lack dedicated medications.

1. Development project utilizing eye drops for the treatment of posterior eye diseases.
2. Eye drop formulation as an adjunct to gene therapy for posterior eye treatment.

Local steroid injection project in collaboration with AimMax. Targeting in osteoarthritis pain management and hypertrophic scar treatment.

- 6 Patent Families
- 140+Patents
- Global Market Coverage

- Inhaled antibiotic project utilizing HCmed's (心誠鎂) proprietary nebulizer.
- Targeting the market gap in local anti-infective treatment for acute and chronic respiratory conditions.

FORMOSA PHARMACEUTICALS, INC. 台新藥股份有限公司


4
BYQLOVI (APP13007) Nanosuspension
Features | License & Reg. | Market | Commercialization
Commercial Engine: Breakthrough Novel Drug for Ocular Surgery Recovery
Rx only
BYQLOVI
(clobetasol propionate ophthalmic suspension) 0.1%
3.5mL
Sterile
ADC APNT

BYQLOVI (APP13007) Nanosuspension

Features | License & Reg. | Market | Commercialization

Combination of Potent Efficacy and Low Risk

POD4, **85%** of patients were completely pain-free.
POD15, **59%** of patients had an inflammation cell count of 0.

Extremely **low risk of IOP elevation (1%)**, addressing the most concerning side effect of potent steroids.

Requires dosing only twice daily (BID), with just one drop per dose, effectively enhancing patient compliance.

Clobetasol propionate

BYQLOVI Ophthalmic Suspension

Clobetasol Propionate Ophthalmic Suspension, 0.05%

For Inflammation and pain following ocular surgery.

FORMOSA PHARMACEUTICALS, INC. 台新藥股份有限公司

BYQLOVI (APP13007) Nanosuspension

Features | License & Reg. | Market | Commercialization



APP13007 Global licensing partners

- ADALVO — Europe & Brazil
- APOTEX (Canadian-Based Global Health Company) — Canada & Mexico
- Cipla — India & South Africa
- CGE 远大健康 CGE HEALTHCARE — Mainland China
- DÁVI — Portugal
- HARROW (Your patients. Our purpose.) — United States
- medvisis (Swiss Healthcare Company) — Switzerland
- RXiLIENT — Southeast Asia
- SAVAL — Latin America
- Samil — South Korea
- tabuk pharmaceuticals — Middle East & N. Africa
- Tzamal BIO-PHARMA — Israel

BYQLOVI (APP13007) Nanosuspension

Features | License & Reg. | Market | Commercialization

APOTEX Canadian-Based Global Health Company

Canada

Submission: Jan 2025
Target Approval: 1H 2026

medvisis Swiss Healthcare Company

Switzerland

Submission: Feb 2025
Target Approval: 2H 2026

FORMOSA PHARMACEUTICALS, INC. 台新藥股份有限公司

Taiwan

Submission: May 2025
Target Approval: 1H 2026

tabuk pharmaceuticals

KSA

Submission: May 2025
Target Approval: 1H 2027

Tzamal BIO-PHARMA

Israel

Submission: Jun 2025
Target Approval: 1H 2028

Cipla



South Africa

Submission: Dec 2025
Target Approval: 2H 2028

BYQLOVI (APP13007) Nanosuspension

Features | License & Reg. | **Market** | Commercialization

Market Potential in Licensed Territories

Cases of Cataract Patients	Cataract Surgery Volume	Steroid Eye Drop Market Size
234Mn	30Mn/yr	$1.38Bn+

BYQLOVI (APP13007) Nanosuspension

Features | License & Reg. | Market | Commercialization

Harrow's Commercial Ecosystem

- **Broad Product Coverage:** Covers a complete product line for dry eye, retina, ophthalmic surgery, and rare/specialty diseases.
- **Diversified Solutions:** Provides branded drugs, generics, over-the-counter (OTC) drugs, etc., satisfying different clinical needs.
- **Diverse Payment Models:** Supports Buy & Bill, commercial insurance, government insurance, and cash payments, ensuring flexible market access.
- **Focus on the Surgical Field:** Committed to building a world-class ophthalmic surgical drug portfolio, with BYQLOVI being a key flagship product..



Harrow (NASDAQ: HROW) 2024 Financial Overview:

- Revenue: US$199M | 5-year CAGR: 32.5%
- EBITDA: US$ 40M | 5-year CAGR: 47.8%

BYQLOVI (APP13007) Nanosuspension

Features | License & Reg. | Market | Commercialization

Harrow plans to conduct a soft launch in Q1 2026 and re-launch BYQLOVI in Q2 2026.

Establish a Beachhead and Gradually Realize Market Penetration Strategy:

Precision Strike

Market Size: ~200k cases/year

Replace **branded drugs and high-priced generics.** Target physicians and patients with high requirements for drug efficacy and safety.

Gradual Expansion

Market Size: ~1 Mn cases/year

Strive to **replace traditional steroid products** with high dosing frequency and long treatment duration.

Market Benchmark

Market Size: ~5Mn cases/year

Become the **standard of care** for post-operative inflammation and pain control.

Exclusive market access model supporting branded drugs: Harrow Access for All (HAFA)

The platform provides simplified PA process services, reducing the administrative burden on physicians prescribing branded drugs.

Eligible commercial insurance patients may have a co-pay as low as $0. Regardless of insurance status, out-of-pocket costs are capped at a fixed amount.

ADC APNT

See the power in the small.

Thank you for your interest

FORMOSA PHARMACEUTICALS, INC.
台新藥股份有限公司

IR@formosapharma.com